HLA-B* 1502 screening: time to clinical practice

Epilepsia. 2010 May;51(5):936-8. doi: 10.1111/j.1528-1167.2010.02549.x.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Anticonvulsants / adverse effects
  • Anticonvulsants / therapeutic use
  • Asians / genetics*
  • Carbamazepine / adverse effects
  • Carbamazepine / therapeutic use
  • Epilepsy / drug therapy
  • Genetic Markers
  • Genetic Testing / statistics & numerical data*
  • Genotype
  • HLA-B Antigens / genetics*
  • HLA-B15 Antigen
  • Humans
  • Predictive Value of Tests
  • Sensitivity and Specificity
  • Stevens-Johnson Syndrome / diagnosis
  • Stevens-Johnson Syndrome / genetics*

Substances

  • Anticonvulsants
  • Genetic Markers
  • HLA-B Antigens
  • HLA-B*15:02 antigen
  • HLA-B15 Antigen
  • Carbamazepine